



# sensei<sup>TM</sup> BIO

## **Sensei Biotherapeutics to Participate in Cantor Fitzgerald's Future of Oncology Virtual Symposium**

March 30, 2023

BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that John Celebi, president and chief executive officer, will participate in a panel titled 'Novel Approaches in Immunotherapy' at Cantor Fitzgerald's Future of Oncology Virtual Symposium on Monday, April 3<sup>rd</sup> at 10:00 a.m. ET.

### **About Sensei Biotherapeutics**

Sensei Biotherapeutics (Nasdaq: SNSE) is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb<sup>TM</sup> (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei's lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditional binding monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4), as well as SNS-103, also a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39. For more information, please visit [www.senseibio.com](http://www.senseibio.com), and follow the company on Twitter @SenseiBio and [LinkedIn](#).

### **Investor Contact:**

Michael Biega  
Senior Director, Investor Relations  
Sensei Biotherapeutics  
[mbiega@senseibio.com](mailto:mbiega@senseibio.com)

### **Media Contact:**

Chris Railey  
Ten Bridge Communications  
[chris@tenbridgecommunications.com](mailto:chris@tenbridgecommunications.com)